PAPER Hasegawa M, Kitaguchi N, Takechi H, Kawaguchi K, Ito K, Kato T, Kato M, Nii N, Yamada S, Ohashi A, Koide S, Hayashi H, Takahashi K, Inaguma D, Yuzawa Y, Tsuboi N

First-in-human study of blood amyloid β removal from early Alzheimer's disease patients with normal kidney function.

Ther Apher Dial. 2022 Jun;26(3):529-536. Epub 2022 Mar 21 PubMed.

PAPER Grifols C, Barceló M, Núñez L, Szczepiorkowski ZM, Boada M, López OL, Páez A

Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study.

Ther Apher Dial. 2023 Oct;27(5):949-959. Epub 2023 May 21 PubMed.

PAPER Lecht S, Haroutiunian S, Hoffman A, Lazarovici P

Rasagiline- a novel MAO B inhibitor in Parkinson's disease therapy.

Ther Clin Risk Manag. 2007 Jun;3(3):467-74. PubMed.

PAPER Annicchiarico R, Federici A, Pettenati C, Caltagirone C

Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Ther Clin Risk Manag. 2007 Dec;3(6):1113-23. PubMed.

PAPER Kubo T, Yamaguchi A, Iwata N, Yamashita T

The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.

Ther Clin Risk Manag. 2008 Jun;4(3):605-15. PubMed.

PAPER Corcia P, Gordon PH

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Ther Clin Risk Manag. 2012;8:359-66. PubMed.

PAPER Ahmed A, Simmons Z

Pseudobulbar affect: prevalence and management.

Ther Clin Risk Manag. 2013;9:483-9. Epub 2013 Nov 29 PubMed.

PAPER Ruangritchankul S, Chantharit P, Srisuma S, Gray LC

Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review.

Ther Clin Risk Manag. 2021;17:927-949. Epub 2021 Sep 4 PubMed.

PAPER Deng CX

Targeted drug delivery across the blood-brain barrier using ultrasound technique.

Ther Deliv. 2010 Dec 1;1(6):819-848. PubMed.

PAPER Nicolazzo JA, Banks WA

Decreased blood-brain barrier expression of P-glycoprotein in Alzheimer's disease: impact on pathogenesis and brain access of therapeutic agents.

Ther Deliv. 2011 Jul;2(7):841-4. PubMed.

PAPER Liu G, Men P

Iron chelation and nanoparticle target delivery in the development of new multifunctional disease-modifying drugs for Alzheimer's disease.

Ther Deliv. 2012 May;3(5):571-4. PubMed.

PAPER Doggui S, Dao L, Ramassamy C

Potential of drug-loaded nanoparticles for Alzheimer's disease: diagnosis, prevention and treatment.

Ther Deliv. 2012 Sep;3(9):1025-7. PubMed.

PAPER Mantha N, Das SK, Das NG

RNAi-based therapies for Huntington's disease: delivery challenges and opportunities.

Ther Deliv. 2012 Sep;3(9):1061-76. PubMed.

PAPER Brazier MW, Mot AI, White AR, Collins SJ

Immunotherapeutic approaches in prion disease: progress, challenges and potential directions.

Ther Deliv. 2013 May;4(5):615-28. PubMed.

PAPER Gu X, Chen H, Gao X

Nanotherapeutic strategies for the treatment of Alzheimer's disease.

Ther Deliv. 2015 Feb;6(2):177-95. PubMed.